Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib + camrelizumab + TACE as first-line treatment in advanced hepatocellular carcinoma
ChiCTR2200058747Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donafenib and camrelizumab in hepatocellular carcinoma (HCC), sponsored by Ruijin Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
donafenibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200058747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058747.